DEUCRAVACITINIB for Pustular psoriasis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 10 adverse event reports in the FDA FAERS database where DEUCRAVACITINIB was used for Pustular psoriasis.
Most Reported Side Effects for DEUCRAVACITINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Drug ineffective | 228 | 9.6% | 0 | 1 |
| Acne | 225 | 9.4% | 0 | 1 |
| Pruritus | 187 | 7.8% | 0 | 2 |
| Rash | 175 | 7.3% | 0 | 0 |
| Erythema | 124 | 5.2% | 0 | 2 |
| Psoriasis | 122 | 5.1% | 0 | 2 |
| Off label use | 101 | 4.2% | 1 | 6 |
| Adverse event | 74 | 3.1% | 0 | 0 |
| Mouth ulceration | 72 | 3.0% | 0 | 1 |
| Folliculitis | 65 | 2.7% | 0 | 2 |
| Headache | 65 | 2.7% | 0 | 0 |
| Product dose omission issue | 61 | 2.6% | 0 | 0 |
| Pain | 60 | 2.5% | 0 | 1 |
| Skin burning sensation | 60 | 2.5% | 0 | 1 |
| Diarrhoea | 46 | 1.9% | 1 | 3 |
Other Indications for DEUCRAVACITINIB
Psoriasis (1,456)
Product used for unknown indication (808)
Psoriatic arthropathy (41)
Eczema (10)
Guttate psoriasis (9)
Dermatitis atopic (8)
Palmoplantar pustulosis (6)
Dermatitis (5)
Erythrodermic psoriasis (5)
Granuloma annulare (5)
Other Drugs Used for Pustular psoriasis
APREMILAST (349)
SECUKINUMAB (317)
ADALIMUMAB (207)
METHOTREXATE (159)
CYCLOSPORINE (157)
ETANERCEPT (146)
INFLIXIMAB (144)
ACITRETIN (129)
USTEKINUMAB (120)
EFALIZUMAB (101)